Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Immunocore Holdings plc, Sarepta Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Immunocore Holdings plc, Sarepta Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Immunocore Holdings plc, Sarepta Therapeutics and Inc.

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company’s products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children’s Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Latest Biotechnology and Immunocore Holdings plc, Sarepta Therapeutics, Inc. Stock News

As of November 26, 2025, Immunocore Holdings plc had a $2.0 billion market capitalization, compared to the Biotechnology median of $220.1 million. Immunocore Holdings plc’s stock is up 36% in 2025, up 3.8% in the previous five trading days and up 24.32% in the past year.

Currently, Immunocore Holdings plc does not have a price-earnings ratio. Immunocore Holdings plc’s trailing 12-month revenue is $379.6 million with a -7.7% net profit margin. Year-over-year quarterly sales growth most recently was 29.3%. There are no analysts providing consensus earnings estimates for the current fiscal year. Immunocore Holdings plc does not currently pay a dividend.

As of November 26, 2025, Sarepta Therapeutics, Inc. had a $2.2 billion market cap, putting it in the 57th percentile of all stocks. Sarepta Therapeutics, Inc.’s stock is down 82.8% in 2025, up 27.8% in the previous five trading days and down 81.66% in the past year.

Currently, Sarepta Therapeutics, Inc. does not have a price-earnings ratio. Sarepta Therapeutics, Inc.’s trailing 12-month revenue is $2.4 billion with a -11.2% net profit margin. Year-over-year quarterly sales growth most recently was -14.5%. Analysts expect adjusted earnings to reach $-2.013 per share for the current fiscal year. Sarepta Therapeutics, Inc. does not currently pay a dividend.

How We Compare Immunocore Holdings plc, Sarepta Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Immunocore Holdings plc, Sarepta Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Immunocore Holdings plc, Sarepta Therapeutics and Inc. Stock Value Grades

Company	Ticker	Value
Immunocore Holdings plc	IMCR	F
Sarepta Therapeutics, Inc.	SRPT	C

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Immunocore Holdings plc has a Value Score of 9, which is Ultra Expensive. Sarepta Therapeutics, Inc. has a Value Score of 49, which is Average.

The Value Stock Winner: No Clear Winner

Neither Immunocore Holdings plc, Sarepta Therapeutics or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Immunocore Holdings plc, Sarepta Therapeutics or Inc. is the better investment when it comes to value.

Immunocore Holdings plc, Sarepta Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
Immunocore Holdings plc	IMCR	D
Sarepta Therapeutics, Inc.	SRPT	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Immunocore Holdings plc has a Growth Score of 27, which is Weak. Sarepta Therapeutics, Inc. has a Growth Score of 32, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither Immunocore Holdings plc, Sarepta Therapeutics or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Immunocore Holdings plc, Sarepta Therapeutics or Inc. is the better investment when it comes to sustainable growth.

Immunocore Holdings plc, Sarepta Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Immunocore Holdings plc	IMCR	C
Sarepta Therapeutics, Inc.	SRPT	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Immunocore Holdings plc has a Earnings Estimate Score of 51, which is Neutral. Sarepta Therapeutics, Inc. has a Earnings Estimate Score of 50, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Immunocore Holdings plc, Sarepta Therapeutics or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Immunocore Holdings plc, Sarepta Therapeutics or Inc. is the better investment when it comes to estimate revisions.

Other Immunocore Holdings plc, Sarepta Therapeutics and Inc. Grades

In addition to Estimate Revisions, Growth and Value, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Immunocore Holdings plc, Sarepta Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Immunocore Holdings plc, Sarepta Therapeutics or Inc. Stock?

Overall, Immunocore Holdings plc stock has a Value Score of 9, Growth Score of 27 and Estimate Revisions Score of 51.

Sarepta Therapeutics, Inc. stock has a Value Score of 49, Growth Score of 32 and Estimate Revisions Score of 50.

Comparing Immunocore Holdings plc, Sarepta Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.